ProstaLund announced that the company has received market approval from the certification body TÜV SÜD for its new platform CoreTherm® Eagle for benign prostatic hyperplasia (BPH /BPE) through a CE marking based on the EU medical device regulations (MDR). CoreTherm® heat treatment is a fast, safe, and effective treatment for benign prostatic hyperplasia (BPH/BPE). The treatment takes less than 15 minutes without surgical intervention.

A great advantage of the method is that the size of the prostate is not a limited factor and the prostate up to 366 ml has been treated. CoreTherm® is performed under local anesthesia and the patient thus avoids anesthesia and overnight stays in the hospital. The treatment is carried out at 27 clinics in the Nordic region and at a smaller number outside the Nordic region.

The platform itself is a masterpiece and CoreTherm® is thus probably the world's best BPE treatment if look at parameters such as treatment results, the ability to treat regardless of the size of the prostate, re-treatment frequency, treatment time, fewer complications compared to surgical procedures, learning time for treating doctors and the cost of a treatment, etc. The company expected to start production in the third quarter of 2023", says CEO Johan Wennerholm in a comment. The new MDR regulatory framework (where MDR stands for Medical Device Regulation) is designed according to an EU regulation (2017/745) developed to ensure the safety and performance of medical devices.

Compared to the previous MDD regulations, updates have been made on which medical devices may be on the market, as well as how to provide and use products. The MDR regulatory framework improves patient safety by introducing stricter methods of assessment and monitoring on the market. It also contains rules for how medical technology companies should carry out product evaluations within the EU.

This ensures that unsafe and non-compliant products and equipment do not end up on the market. The MDR regulations cover all companies that sell medical devices to EU Member States, Switzerland, and member states within the EEA.